GeneDx Holdings (WGS) Share-based Compensation (2020 - 2026)

GeneDx Holdings (WGS) has reported Share-based Compensation for 7 consecutive years, with $12.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 203.44% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $40.3 million (up 196.68% YoY), while the FY2025 annual figure was $32.2 million, up 251.96% from the prior year.
• Share-based Compensation advanced to $12.1 million in Q1 2026 per WGS's latest filing, from $9.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $154.4 million in Q2 2022 and bottomed at -$130.0 million in Q4 2022.
• Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $3.8 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 29857.42% — and 2024, when it sank 1039.58%.
• GeneDx Holdings' Share-based Compensation stood at -$130.0 million in 2022, then jumped by 100.04% to $51000.0 in 2023, then jumped by 5478.43% to $2.8 million in 2024, then jumped by 243.76% to $9.8 million in 2025, then rose by 23.58% to $12.1 million in 2026.
• Business Quant data shows WGS's Share-based Compensation at $12.1 million in Q1 2026, $9.8 million in Q4 2025, and $10.6 million in Q3 2025.